

increase CD4⁺Foxp3⁺ Treg cells in spleens and LNs in the present study (data not shown). Treatment of splenocytes with HGF in vitro during CII restimulation did not increase Foxp3⁺ Treg cells either. In contrast, repeated treatment with HGF in vivo gradually increased IL-10 production by DCs (Figs. 4D and 8F). These results indicated that the augmented IL-10 production by CD4⁺ T cells was not mediated by Foxp3⁺ Treg cells but, at least in vivo, by up-regulation of IL-10 production by DCs after repeated HGF treatment. The precise mechanism of induction of IL-10-producing CD4⁺ T cells by HGF is not clear at present and should be further investigated.

IL-10 also enhances the formation of Th2 cells by down-regulating IL-12 production by DCs (52). Moreover, some reports also emphasize the importance of IL-10 in the induction of Th2 cells (53, 54). As described above, after T cells were primed with Ag, HGF in the presence of continuous Ag stimulation increased IL-10 production by immunocytes, including DCs, along with suppression of IL-12 production by DCs (Figs. 4, 7, and 8), indicating that under continuous Ag stimulation HGF could induce Th2-type immune responses in the chronic phase. In fact, in the chronic phase of CII-induced immune responses, repeated treatment with HGF up-regulated both IL-4 and IL-10 production in T cells (Figs. 7 and 8). These results were consistent with a recent report that HGF ameliorates the progression of experimental autoimmune myocarditis with the induction of Th2 cytokines (23). We also confirmed that HGF enhanced mRNA expression of GATA-3, which specifies Th2 cell development, in CD4⁺ T cells in the chronic inflammatory phase (Fig. 8E). Th2-type immune responses suppress Th1-type immune responses (55), and a recent study reported that IL-4 significantly suppresses the development of Th17 cells, a new subset of effector CD4⁺ T cells distinct from Th1 or Th2 cells (56). However, in the current study we found that neutralization of IL-4 in vitro did not increase IL-17 production by splenocytes after CII restimulation (data not shown). Collectively, HGF would enhance Th2-type immune responses in chronic inflammation, thus inhibiting both Th1- and Th17-type responses at least in vivo.

Recent studies clarified that IL-17 produced by Th17 cells has a crucial role in the induction of autoimmune tissue injury (30–32, 57, 58). Accumulating evidence indicates that IL-17 plays an essential role not only in the induction of autoimmune arthritis (30, 31) but also in the subsequent bone destruction (32). In the current study, HGF potently suppressed IL-17 production by draining LN cells after in vitro CII restimulation in the early stage of Ag-induced immune responses (Fig. 5). Further, in addition to the sensitization phase, even in the chronic inflammation phase with joint destruction HGF significantly suppressed IL-17 production by spleen cells (Fig. 7E). Moreover, HGF significantly suppressed DC production of IL-23 (Fig. 3C), which is now recognized as a very important cytokine for IL-17 secretion from activated CD4⁺ T cells (57, 59). These results indicated that HGF would be beneficial in treating autoimmune arthritis.

TGF- β is an immunosuppressive growth factor. Some phenotypes of T cells function as Treg cells by producing TGF- β . In contrast, the role of TGF- β in the induction of the Th17 cell lineage to promote an autoimmune response has been recently highlighted (52, 60, 61). Generally, HGF counteracts the biological functions of TGF- β such as promoting fibrosis (13, 14). In the immune response, however, the relation between HGF and TGF- β differs among experimental systems. HGF suppresses acute and chronic rejection in a mouse model of cardiac allograft transplantation with unexpectedly enhanced expression of TGF- β mRNA (22). In contrast, in allergic airway inflammation HGF did not up-regulate TGF- β production in the lung (24). In the present study on arthritis, HGF reduced mRNA

expression of TGF- β in CD4⁺ T cells at both early and chronic phases (data not shown).

Generally, exogenously administered HGF proteins vanish from organs within several hours (44). In a preliminary study, we confirmed that s.c. injection of HGF protein (10 μ g per mouse) once daily failed to suppress the Ag-induced T cell priming and development of CII-induced arthritis (data not shown). Previously, we used a hydrodynamic-based transfer system to deliver HGF effectively and confirmed that a slight but continuous up-regulation of HGF protein in the sera potently suppressed OVA/alum-induced T cell priming and allergic airway inflammation (24). However, this delivery system could not be applied to an experimental model of arthritis due to an anatomical narrowing of the tail vein provoked by injection of CII/CFA into the subcutis of the tail. Thus, to achieve a controlled release of HGF, we adopted biodegradable gelatin hydrogels as carriers of HGF. We previously confirmed that when this gelatin/HGF complex was s.c. injected into mice, HGF was delivered under a controlled release based on hydrogel degradation and that the degradation occurred over 10 days (37). We reconfirmed that controlled release of HGF was achieved using a gelatin/rhHGF complex by examining the time course of concentration of HGF in the sera (Table I). In this study, the controlled release of HGF potently suppressed Ag-induced T cell priming and development of CII-induced arthritis. Thus, gelatin hydrogels would be an ideal carrier for HGF to exhibit its biological effects, and further application in various models can be expected.

Pulmonary fibrosis is often associated with RA and is one of the major causes of death in RA patients (62). To date, several articles, including our own, reported that HGF inhibits the progression of experimental pulmonary fibrosis (15, 63, 64). Considering the simultaneous effect on pulmonary fibrosis and arthritis, HGF could be an attractive tool in treating RA with pulmonary involvement in a clinical situation. In contrast, in the clinical use of HGF the possibility of promoting tumor progression should be considered. Therefore, for practical usage of HGF in clinical situations further studies should be performed.

In summary, our results in the present study indicated that HGF could exhibit its immunosuppressive effects in different manners at different stages of immune response. In the early phase of Ag-induced immune responses HGF potently suppressed DC function, thus inhibiting T cell priming by Ag. In contrast, during chronic inflammation HGF gradually increased IL-10 production by DCs, which subsequently induced IL-10 producing T cells and Th2-type immune responses. The precise mechanism should be further investigated in detail.

Acknowledgment

We thank K. Kurosaki for technical assistance.

Disclosures

The authors have no financial conflict of interest.

References

- Gohda, E., H. Tsubouchi, H. Nakayama, S. Hirono, O. Sakiyama, K. Takahashi, H. Miyazaki, S. Hashimoto, and Y. Daikuhara. 1988. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. *J. Clin. Invest.* 81: 414–419.
- Miyazawa, K., H. Tsubouchi, D. Naka, K. Takahashi, M. Okigaki, N. Arakaki, H. Nakayama, S. Hirono, O. Sakiyama, K. Takahashi, et al. 1989. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. *Biochem. Biophys. Res. Commun.* 163: 967–973.
- Nakamura, T., T. Nishizawa, M. Hagiya, T. Seki, M. Shimonishi, A. Sugimura, K. Tashiro, and S. Shimizu. 1989. Molecular cloning and expression of human hepatocyte growth factor. *Nature* 342: 440–443.
- Stoker, M., E. Gherardi, M. Perryman, and J. Gray. 1987. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. *Nature* 327: 239–242.

5. Zamegar, R., and G. K. Michalopoulos. 1995. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. *J. Cell Biol.* 129: 1177-1180.
6. Bardelli, A., P. Longati, D. Albero, S. Goruppi, C. Schneider, C. Ponzetto, and P. M. Comoglio. 1996. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. *EMBO J.* 15: 6205-6212.
7. Huh, C. G., V. M. Factor, A. Sanchez, K. Uchida, E. A. Conner, and S. S. Thorgeirsson. 2004. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. *Proc. Natl. Acad. Sci. USA* 101: 4477-4482.
8. Trusolino, L., and P. M. Comoglio. 2002. Scatter-factor and semaphoring receptors: cell signaling for invasive growth. *Nat. Rev. Cancer* 2: 289-300.
9. Imaizumi, Y., H. Murota, S. Kanda, Y. Hishikawa, T. Koji, T. Taguchi, Y. Tanaka, Y. Yamada, S. Ikeda, T. Kohno, et al. 2003. Expression of the c-met proto-oncogene and its possible involvement in liver invasion in adult T-cell leukemia. *Clin. Cancer Res.* 9: 181-187.
10. Siegfried, J. M., L. A. Weissfeld, P. Singh-Kaw, R. J. Weyant, J. R. Testa, and R. J. Landreneau. 1997. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. *Cancer Res.* 57: 433-439.
11. To, Y., M. Dohi, K. Matsumoto, R. Tanaka, A. Sato, K. Nakagome, T. Nakamura, and K. Yamamoto. 2002. A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line. *Am. J. Respir. Cell Mol. Biol.* 27: 220-226.
12. Wislez, M., N. Rabbe, J. Marchal, B. Milleron, B. Crestani, C. Mayaud, M. Antoine, P. Soler, and J. Cadranel. 2003. Hepatocyte growth factor production by neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. *Cancer Res.* 63: 1405-1412.
13. Mizuno, S., T. Kurosawa, K. Matsumoto, Y. Mizuno-Horikawa, M. Okamoto, and T. Nakamura. 1998. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. *J. Clin. Invest.* 101: 1827-1834.
14. Ueki, T., Y. Kaneda, H. Tsutsui, K. Nakanishi, Y. Sawa, R. Morishita, K. Matsumoto, T. Nakamura, H. Takahashi, E. Okamoto, and J. Fujimoto. 1999. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. *Nat. Med.* 5: 226-230.
15. Dohi, M., T. Hasegawa, K. Yamamoto, and B. C. Marshall. 2000. Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* 162: 2302-2307.
16. van der Voort, R., T. E. I. Taher, R. M. J. Keehnen, L. Smit, M. Groenink, and S. T. Pals. 1997. Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway. *J. Exp. Med.* 185: 2121-2131.
17. Weimar, I. S., D. de Jong, E. J. Muller, T. Nakanura, J. M. van Gorp, G. C. de Gast, and W. R. Gerritsen. 1997. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via $\alpha_4\beta_1$ and $\alpha_3\beta_1$ integrins. *Blood* 89: 990-1000.
18. Adams, D. H., L. Harvath, D. P. Bottaro, R. Interrante, G. Catalano, Y. Tanaka, A. Strain, S. G. Hubscher, and S. Shaw. 1994. Hepatocyte growth factor and macrophage inflammatory protein 1b: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. *Proc. Natl. Acad. Sci. USA* 91: 7144-7148.
19. Kurz, S. M., S. S. Diebold, T. Hieronymus, T. C. Gust, P. Bartunck, M. Sachs, W. Birchmeier, and M. Zenke. 2002. The impact of c-met/scatter factor receptor on dendritic cell migration. *Eur. J. Immunol.* 32: 1832-1838.
20. Scarpino, S., A. Stoppacciaro, F. Ballerini, M. Marchesi, M. Prat, M. C. Stella, S. Sozzani, P. Allavena, A. Mantovani, and L. P. Ruco. 2000. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. *Am. J. Pathol.* 156: 831-837.
21. Kretzschmar, M., J. Doody, and J. Massague. 1997. Opposing BMP and EGF signaling pathways converge on the TGF- β family mediator Smad1. *Nature* 389: 618-622.
22. Yamamura, K., K. Ito, K. Tsukioka, Y. Wada, A. Makiuchi, M. Sakaguchi, T. Akashima, M. Fujimori, Y. Sawa, R. Morishita, et al. 2004. Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation. *Circulation* 110: 1650-1657.
23. Futamatsu, H., J. Suzuki, S. Mizuno, N. Koga, S. Adachi, H. Kosuge, Y. Maejima, K. Hirao, T. Nakamura, and M. Isobe. 2005. Hepatocyte growth factor ameliorates the progression of experimental autoimmune myocarditis: a potential role for induction of T helper 2 cytokines. *Circ. Res.* 96: 823-830.
24. Okunishi, K., M. Dohi, K. Nakagome, R. Tanaka, S. Mizuno, K. Matsumoto, J. Miyazaki, T. Nakamura, and K. Yamamoto. 2005. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. *J. Immunol.* 175: 4745-4753.
25. Ito, W., A. Kanehiro, K. Matsumoto, A. Hirano, K. Ono, H. Maruyama, M. Kataoka, T. Nakamura, E. W. Gelfand, and M. Tanimoto. 2005. Hepatocyte growth factor attenuates airway hyperresponsiveness, inflammation, and remodeling. *Am. J. Respir. Cell Mol. Biol.* 32: 268-280.
26. Kuroiwa, T., T. Iwasaki, T. Imado, M. Sekiguchi, J. Fujimoto, and H. Sano. 2006. Hepatocyte growth factor prevents lupus nephritis in a murine model of chronic graft-versus-host disease. *Arthritis. Res. Ther.* 8: R123.
27. Hale, L. P., and B. F. Haynes. 2001. Pathology of rheumatoid arthritis and associated disorders. In *Arthritis and Allied Conditions: A Textbook of Rheumatology*, 14th Ed., Vol. 1. W. J. Koopman, ed. Williams & Wilkins Press, Baltimore, pp. 1103-1127.
28. Dolhain, R. J., A. N. van der Heiden, N. T. ter Haar, F. C. Breedveld, and A. M. Miltenburg. 1996. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. *Arthritis Rheum.* 39: 1961-1969.
29. Smolen, J. S., M. Tohidast-Arkad, A. Gal, M. Kunaver, G. Eberl, P. Zenz, A. Falus, and G. Steiner. 1996. The role of T-lymphocytes and cytokines in rheumatoid arthritis. *Scand. J. Rheumatol.* 25: 1-4.
30. Miossec, P. 2003. Interleukin-17 in rheumatoid arthritis. *Arthritis Rheum.* 46: 594-601.
31. Nakae, S., S. Saijo, R. Horai, K. Sudo, S. Mori, and Y. Iwakura. 2003. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. *Proc. Natl. Acad. Sci. USA* 100: 5986-5990.
32. Sato, K., A. Suematsu, K. Okamoto, A. Yamaguchi, Y. Morishita, Y. Kadono, S. Tanaka, T. Kodama, S. Akira, Y. Iwakura, et al. 2006. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. *J. Exp. Med.* 203: 2673-2682.
33. Maruotti, N., F. P. Cantatore, E. Crivellato, A. Vacca, and D. Ribatti. 2006. Angiogenesis in rheumatoid arthritis. *Histol. Histopathol.* 21: 557-566.
34. Koch, A. E., M. M. Halloran, S. Hosaka, M. R. Shah, C. J. Haskell, S. K. Baker, R. J. Panos, G. K. Haines, G. L. Bennett, R. M. Pupe, and N. Ferrara. 1996. Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis. *Arthritis Rheum.* 39: 1566-1575.
35. Yukioka, K., M. Inaba, Y. Furumitsu, M. Yukioka, T. Nishino, H. Goto, Y. Nishizawa, and H. Morii. 1994. Levels of hepatocyte growth factor in synovial fluid and serum of patients with rheumatoid arthritis and release of hepatocyte growth factor by rheumatoid synovial fluid cells. *J. Rheumatol.* 21: 2184-2189.
36. Feuerhahn, A. J., M. Borsari, C. Seidel, A. Sundan, L. Leistad, M. Ostensen, and A. Faxvaag. 2001. Elevated levels of osteopontin (OPN) and hepatocyte growth factor (HGF) in rheumatoid arthritis. *Scand. J. Rheumatol.* 30: 229-234.
37. Ozeki, M., T. Ishii, Y. Hirano, and Y. Tabata. 2001. Controlled release of hepatocyte growth factor from gelatin hydrogels based on hydrogel degradation. *J. Drug. Target.* 9: 461-471.
38. Oe, S., Y. Fukunaka, T. Hirose, Y. Yamaoka, and Y. Tabata. 2003. A trial on regeneration therapy of rat liver cirrhosis by controlled release of hepatocyte growth factor. *J. Control. Release* 88: 193-200.
39. Okunishi, K., M. Dohi, K. Nakagome, R. Tanaka, and K. Yamamoto. 2004. A novel role of cysteinyl leukotrienes to promote dendritic cell activation in the antigen-induced immune responses in the lung. *J. Immunol.* 173: 6393-6402.
40. Kuroda, E., and U. Yamashita. 2003. Mechanisms of enhanced macrophage-mediated prostaglandin E₂ production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. *J. Immunol.* 170: 757-764.
41. Dabbagh, K., M. E. Dahl, P. Stepick-Biek, and D. B. Lewis. 2002. Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. *J. Immunol.* 168: 4524-4530.
42. Sagawa, K., K. Nagatani, Y. Komagata, and K. Yamamoto. 2005. Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice. *Arthritis Rheum.* 52: 1920-1928.
43. Nakagome, K., M. Dohi, K. Okunishi, Y. Komagata, K. Nagatani, R. Tanaka, J. Miyazaki, and K. Yamamoto. 2005. In vivo IL-10 gene delivery suppresses airway eosinophilia and hyperreactivity by down-regulating APC functions and migration without impairing the antigen-specific systemic immune response in a mouse model of allergic airway inflammation. *J. Immunol.* 174: 6955-6966.
44. Michalopoulos, G. K., and R. Appasamy. 1993. Metabolism of HGF-SF and its role in liver regeneration. *EXS* 65: 275-283.
45. Zheng, W., and R. A. Flavell. 1997. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. *Cell* 89: 587-596.
46. Kapsenberg, M. L. 2003. Dendritic-cell control of pathogen-driven T-cell polarization. *Nat. Rev. Immunol.* 3: 984-993.
47. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. *Nature* 392: 245-252.
48. Rutella, S., G. Bonanno, A. Procoli, A. Mariotti, D. G. de Ritis, A. Curti, S. Danese, G. Pessina, S. Pandolfi, F. Natoni, et al. 2006. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10^{hi}/IL-12^{low} accessory cells with dendritic-cell features. *Blood* 108: 218-227.
49. Fehérvári, Z., and S. Sakaguchi. 2004. CD4⁺ Tregs and immune control. *J. Clin. Invest.* 114: 1209-1217.
50. Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J. E. de Vries, and M. G. Roncarolo. 1997. A CD4⁺ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. *Nature* 389: 737-742.
51. Hawrylowicz, C. M., and A. O'Garra. 2005. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. *Nat. Rev. Immunol.* 5: 271-283.
52. De Smedt, T., M. Van Mechelen, G. De Becker, J. Urbain, O. Leo, and M. Moser. 1997. Effect of interleukin-10 on dendritic cell maturation and function. *Eur. J. Immunol.* 27: 1229-1235.
53. Liu, L., B. E. Rich, J. Inobe, W. Chen, and H. L. Weiner. 1998. Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4⁺ T cells to secrete IL-4. *Int. Immunol.* 10: 1017-1026.
54. Ballic, A., Y. M. Hareus, M. D. Taylor, F. Brombacher, and R. M. Maizels. 2006. IL-4R signaling is required to induce IL-10 for the establishment of Th2 dominance. *Int. Immunol.* 18: 1421-1431.

55. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon- γ . *Annu. Rev. Immunol.* 15: 749–795.
56. Mangan, P. R., L. E. Harrington, D. B. O'Quinn, W. S. Helms, D. C. Bullard, C. O. Elsom, R. D. Hatton, S. M. Wahl, T. R. Schoeb, and C. T. Weaver. 2006. Transforming growth factor- β induces development of the Th17 lineage. *Nature* 441: 231–234.
57. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Matsson, B. Basham, S. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. *J. Exp. Med.* 201: 233–240.
58. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4⁺ T cells regulates tissue inflammation by producing interleukin 17. *Nat. Immunol.* 6: 1133–1141.
59. Aggarwal, S., N. Ghilardi, M. H. Xie, F. J. de Sauvage, and A. L. Gurney. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. *J. Biol. Chem.* 278: 1910–1914.
60. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGF β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity* 24: 179–189.
61. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cell. *Nature* 441: 235–238.
62. Jindal, S. K., and R. Agarwal. 2005. Autoimmunity and interstitial lung disease. *Curr. Opin. Pulm. Med.* 11: 438–446.
63. Yaekashiwa, M., S. Nakayama, K. Ohnuma, T. Sakai, T. Abe, K. Satoh, K. Matsumoto, T. Nakanura, T. Takahashi, and T. Nukiwa. 1997. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. *Am. J. Respir. Crit. Care Med.* 156: 1937–1944.
64. Watanabe, M., M. Ebina, F. M. Orson, A. Nakamura, K. Kubo, K. Kubota, D. Koinuma, K. Akiyama, M. Maemondo, S. Okouchi, et al. 2005. Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. *Mol. Ther.* 12: 58–67.

T Cell Receptor Gene Therapy for Autoimmune Diseases

KEISHI FUJIO, TOMOHISA OKAMURA, AKIKO OKAMOTO,
AND KAZUHIKO YAMAMOTO

*Department of Allergy and Rheumatology, Graduate School of Medicine,
The University of Tokyo, Tokyo, Japan*

ABSTRACT: The current quality of autoimmune disease treatments is not satisfactory in regard to efficacy and safety. Antigen-specific immunotherapy is a future therapy that could achieve maximal efficacy with minimal adverse effects. T cells are essential components in antigen-specific immunity. However, we do not have a sufficient strategy for manipulating antigen-specific T cells. We propose that T cell receptor (TCR) gene transfer is a hopeful approach for antigen-specific immunotherapy. We confirmed the efficacy of TCR gene therapy in animal models of systemic autoimmune disease and arthritis. In lupus-prone NZB/W F1 mice, nucleosome-specific TCR and CTLA4Ig transduced cells suppressed autoantibody production and nephritis development. In the therapeutic experiment of collagen-induced arthritis (CIA), arthritis-related TCRs were isolated from single T cells accumulating in the arthritis site. Arthritis-related TCR and TNFR1g transduced cells or TCR and Foxp3 transduced cells suppressed arthritis progression and bone destruction. Therefore, engineered antigen-specific cells manipulated to express appropriate functional genes could be applied to specific immunotherapy.

KEYWORDS: autoimmune diseases; antigen-specific T cells; gene transfer; T cell receptor

INTRODUCTION

Rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type 1 diabetes are regarded as diseases associated with autoimmunity. These autoimmune diseases are relatively common disorders affecting about 5% of the population, predominantly women.¹ Current treatment of the autoimmune diseases is composed of nonspecific immunosuppressive drugs, such as corticosteroids and cytotoxic reagents. Though nonspecific immunosuppressive therapy has improved clinical outcome of patients in autoimmune diseases, it is

Address for correspondence: Keishi Fujio, Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113, Japan. Voice: +81-3-3815-5411; fax: +81-3-3815-5954.
kfujio-ky@umin.ac.jp

Ann. N.Y. Acad. Sci. 1110: 222–232 (2007). © 2007 New York Academy of Sciences.
doi: 10.1196/annals.1423.024

accompanied by several serious adverse effects. Since cytokines play a pivotal role in immune reactions, application of cytokines has been extensively studied to control autoimmune diseases. Systemic administration of suppressive cytokines, such as transforming growth factor (TGF)- β , interleukin (IL)-4, and IL-10 showed a significant efficacy in models of autoimmune diseases. Some of these agents seem to work by shifting the balance of immune deviation. However, systemic cytokine therapy potentially leads to deleterious side effects, as in the case of recombinant human IL-4.² On the other hand, cytokine-blocking therapies have been successful and will continue to serve as important strategies in many autoimmune diseases. However, because such strategies still have important drawbacks, including severe infections,³ it will also be necessary to explore other specific immunotherapies.

Autoantigens for autoreactive T cells and autoantibodies have been extensively explored in various autoimmune diseases. These explorations are important not only for understanding the pathogenesis of autoimmune diseases, but also for establishing antigen-specific immunotherapies. If possible, suppression of the initial activation of antigen-specific T cells is feasible because intervention appears to be less effective on established pathogenic T cells. However, the majority of patients who require clinical treatment have full-blown autoimmune disease, and this approach would not be adequate. In advanced autoimmune diseases, an immune response to a single epitope on a self-antigen at the start of the disorder can trigger immune responses to adjacent epitopes on the same molecule or to other epitopes on related molecules. This phenomenon is called "epitope spreading." Although the precise impact of the epitope spreading is not evident in the entire autoimmune process, some researchers argue against antigen-specific immunotherapy because of the difficulties of predicting such expanding autoimmune reactions. However, we propose that epitope spreading is not the sole mechanism of the T cell-related pathogenesis of autoimmune diseases and that clonal restriction of T cells occurs in the late phase of autoimmunity. In this context, antigen-specific immunotherapy would be feasible, even for established autoimmune diseases. T cell receptor (TCR) gene transfer could be one of the possible strategies.

EVALUATION OF ANTIGEN-SPECIFIC T CELLS IN AUTOIMMUNE DISEASES

The model of epitope spreading or determinant spreading has been generally accepted in autoimmunity.^{4,5} With respect to T cells, this is a diversification of specificity from the initial limited epitope-specific immune response to a hierarchical cascade of autoreactive T cell specificities. This model could explain the pathway of infection-induced autoimmunity. On the basis of this idea, the initial phase of the autoimmune reaction might be invoked by a few activated T cells against limited numbers of epitopes. These T cells may

be cross-reactive to both microbial epitopes and self-epitopes. On the other hand, in the late phase of the disorders, the reactive epitopes might spread and T cells recognizing a variety of different epitopes on the several different self-molecules would be activated. However, if epitope spreading is the only mechanism involved in the T cell immune responses in autoimmune disorders, development of effective antigen-specific immunotherapies will be difficult, because target epitopes and molecules will always have the potential to spread, and it would be difficult to define the pattern of spreading in a chronic human autoimmune disorder.

To verify the presence of epitope spreading throughout the autoimmune process, it is important to detect how specific T cells behave within the lymphocyte population in the pathological lesions. Previously, our group established a method to analyze accumulated T cell clones using RT-PCR and single-strand conformation polymorphism (SSCP) on TCR messages.⁵ With this method, the same clones were found to exist in different joints, of an RA patient.^{5,6} These results clearly suggested the uniformity of immune responses in RA throughout the arthritic lesions. In the case of HTLV-1 env-pX transgenic mice, which exhibit spontaneous symmetrical arthritis similar to human RA,⁷ there were vigorous accumulations of T cells in the joints, but they were different among the different lesions in the early stage.⁸ In the middle stage, several identical clones were accumulated in the different lesions. In the late stage, the majority of the accumulated clones exist uniformly in several arthritic lesions. The number of the dominant clones did not necessarily increase. These results in mice also suggested the relative uniformity of autoimmune responses in the pathological lesions.

We have observed similar clonal restriction in several spontaneous autoimmune animal models.^{9,10} Moreover, oligoclonally expanded insulin-reactive T cells were identified in the pancreatic draining lymph nodes from type 1 diabetes patients with prolonged disease durations.¹¹ A limited T cell oligoclonality as a "driver clone" in autoimmunity was described in experimental autoimmune encephalomyelitis (EAE).^{12,13} In polymyositis patients, several T cell clones persisted for several years in blood T lymphocytes and consecutive muscle biopsy specimens.¹⁴ On the basis of these observations, we now speculate that epitope spreading does not necessarily work in the late phase of the disease progression, and it is possible that some form of clonal restriction of T cells occurs in autoimmune disorders. Some restricted T cell clones directed toward certain target self-antigens might be sustained. Avidity maturation of a pathogenic T cell population may be the decisive event in the progression of benign inflammation to full-blown autoimmune disease.¹⁵ Therefore, it is feasible to suppress sustained pathologic responses without global immunosuppression.

In immune responses to foreign antigens, T cell responses are dominated by few clonotypes.¹⁶ This clonal selection and dominance may be due to the competitive advantages of higher-affinity receptor, duration of TCR-pMHC

interaction, or affinity threshold.¹⁷ In viral infections, clonal T cell “immuno-domination” occurs in CD8+ T cells, probably because of proliferation advantages, differences of TCR affinity, or co-signal requirements.¹⁸ Hence, the clonal restriction of T cells is not a behavior specific to these diseases, but can be considered as an universal phenomenon.

TCR GENE TRANSFER FOR CONTROLLING AUTOIMMUNE DISEASES

In the application of T cell targeted antigen-specific immunotherapy, there are several technical difficulties in the establishment of autoantigen-specific T cells. Usually the culture should be performed without the information of appropriate autoantigens. We have to select a candidate autoantigen in cloning culture of autoantigen-specific T cells based on the limited information. Moreover, there is no guarantee that *in vitro* established T cell clones represent real disease-associated T cells, mainly because *in vivo* activated T cells are more easily rendered in activation-induced cell death. Therefore, we attempted to produce inflammation-associated T cells by gene transfer of TCRs obtained *in vivo*.

Reconstitution of Antigen-Specific T Cells By TCR Gene Transfer

TCRs of the accumulated T cell clones in the inflammatory lesions can be visualized by RT-PCR/SSCP analysis. We attempted to obtain a pair of full-length cDNAs encoding alpha and beta chains of TCR expressed in a single cell in the lesion. We can reconstitute TCR function by expressing them with gene transfer to self T cells. For the gene transfer to lymphocytes, we have established a highly efficient retrovirus vector system with PLATE and pMX. PLATE is a packaging cell transfected gag-pol and env segment separately. Two independent monocistronic retrovirus vectors harboring alpha and beta TCR cDNAs were generated. For the first study, the class II MHC-restricted alpha and beta TCR genes specific for chicken OVA were used. These TCR genes were cloned from TCR transgenic mice designated DO11.10. These TCRs were transduced to splenocytes from BALB/c mice. The results indicated that alpha and beta TCR gene transfer into peripheral T cells reconstituted the antigen-specific immunity.¹⁹ The amount of TCR expression and both the *in vitro* and *in vivo* antigen-specific functions were comparable to those obtained with splenocytes from DO11.10 transgenic mice. Moreover, DO11.10 TCR and IL-10-co-transduced CD4-positive T cells suppressed delayed type hypersensitivity to OVA, strongly compared to IL-10-transduced polyclonal CD4-positive T cells (Okamura *et al.*, unpublished observation).

Gene Therapy of a Model of Systemic Autoimmune Disease

We next attempted to use this TCR gene transfer to control autoimmune disorders. The target was lupus-prone NZB/W F1 mice, which spontaneously develop a lupus-like syndrome and nephritis. Anti-DNA antibodies are believed to be one of the major pathogenic autoantibodies for the nephritis. Datta and others have pointed out that nucleosome is a major immunogen in SLE.^{20,21} Since DNA and nucleosome are physically associated, it is speculated that nucleosome-reactive T cells help the activation of anti-DNA-specific B cells as the hapten-carrier model. Therefore, we tried to generate nucleosome-specific T cells with an immunosuppressive function.²² We selected CTLA4Ig as a suppressive molecule. TCR cDNAs were engineered on the basis of the published sequence of nucleosome-specific TCRs by fusing TCR V region sequence, synthesized CDR3 sequence, and TCR J-C region sequence. They were V alpha 13 and V beta 4. This TCR recognizes the immunodominant I-A^d-restricted nucleosomal epitope.

In our usual experimental protocol, the proportion of clonotypic TCR expression cells with two transferred TCR genes was estimated to be about 25% in CD4 + T cells. The introduction of TCR was found to reconstitute the specificity for the nucleosome. We then performed triple gene transfer together with CTLA4Ig to generate regulatory T cells (FIG. 1). Our calculations showed that approximately 10% of the total CD4-positive cells expressed all three genes. The CTLA4Ig secreted from transduced T cells blocked the proliferation of the polyclonal T cell population. The TCR and CTLA4Ig transduced cells showed the increase of CTLA4Ig secretion on T cell activation in the presence of DCs. A million of the nucleosome-specific regulatory T cells engineered by the triple genes were then transferred into 10-week-old NZB/W F1 mice. The mice were monitored for proteinuria. By week 22, all of the control mice that had received PBS, cells transferred with mock vectors, TCR alone, and CTLA4Ig started to develop severe nephritis diagnosed by the presence of persistent proteinuria of more than 300 mg/dL. By 30 weeks of age, the majority of these control mice showed severe proteinuria. However, none of the mice treated with cells transferred by the TCRs and CTLA4Ig showed excess proteinuria. The kidneys of the control mice showed severe glomerulonephritis with membranoproliferation, glomerular sclerosis, and tubular casts. The treated mice had mild glomerular disease with less deposition of IgG and complement, especially in the capillary loop. The autoantibodies usually found in NZB/W F1 mice were measured in the sera from different groups. The elevations of anti-dsDNA and anti-histone antibodies were suppressed at 22 weeks of age in the TCR and CTLA4Ig-treated mice. The T cell-dependent humoral response to active immunization of OVA was also analyzed. The level of anti-OVA IgG antibody titer was not significantly different from those of the control mice, indicating there was not an overt systemic immunosuppression of the triple gene-treated mice.




FIGURE 1. Experimental outlines of TCR gene transfer for systemic autoimmune diseases. Therapeutic effect of nucleosome-specific CTLA4Ig-producing T cells in lupus-prone NZB/W F1 mice is shown.

Gene Therapy of Arthritis with Inflamed Paw Homing TNFR1g-Producing T Cells

In order to obtain the whole TCR information from pathological lesions, we developed a method to clone a pair of full-length TCR cDNAs from a single cell accumulated in the inflamed joints of DBA/1 mice with collagen-induced arthritis.²³ Cloning of full-length cDNA encoding TCR was already established.²⁴ Single cell sorting with CD4+ and V beta 8.1/8.2-positive cells was performed and TCR messages were amplified with 3-step nested PCR using a fixed V beta primer and multiple V alpha primers. We then compared the clones obtained from the single cells with accumulated clones observed in the arthritic joints using the RT-PCR/SSCP method. Some TCRs from sorted single cells were actually identical to major accumulated clones in the joints. The full-length TCR cDNAs were subcloned into retrovirus vectors and transferred to DBA/1 splenocytes. Interestingly, some of the pairs of TCR were found to be not specific to immunized type II collagen, but reactive to self-antigen, because TCR-transferred cells proliferated in the culture with DCs from normal and arthritic mice. The carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeling experiments showed that such TCR-transduced cells accumulated and proliferated in the arthritic joints. We next performed a therapeutic experiment using the triple gene-engineered T cells. In this experiment, soluble fusion protein of TNF receptor p75 and Fc domain of IgG2a (TNFR1g) was used as a regulatory molecule. We selected one of the TCR pairs, B47, which expanded in the arthritic paws. Control cells were transduced with either B47 alone or TNFR1g alone. In terms of the arthritis score as well as the incidence of severe arthritis, only B47 plus TNFR1g-transduced cells significantly suppressed the arthritis (FIG. 2A). Interestingly, the serum concentration of TNFR1g was not the main determinant of arthritis suppression in the B47+TNFR1g group, because the serum concentrations of TNFR1g protein in the B47+TNFR1g group were equivalent to those in the TNFR1g group. In contrast, the amount




FIGURE 2. Experimental outlines of TCR gene transfer for collagen-induced arthritis. (A) and (B) illustrate therapeutic effect of paw-directed TNFRlg-producing T cells and paw-directed Foxp3-expressing T cells.

of TNFRlg in the paws of the B47+TNFRlg group was significantly higher than that in the paws of the TNFRlg group. Therefore, local accumulation of the TNFRlg transcript suppressed arthritis in the B47+TNFRlg group, and so biological agents producing T cells may have the advantage over the conventional biological agents that depend on serum concentration. A reduced serum concentration may be associated with less systemic immunosuppression.

Gene Therapy of Arthritis with Inflamed Paw Homing Foxp3-Expressing T Cells

Foxp3 is reported to be the key regulator for regulatory T cells. Several groups have reported that regulatory T cells are accumulated in the joints of arthritis patients.^{25,26} Joint accumulating CD4⁺CD25⁺ T cells displayed an increased suppressive capacity compared with blood CD4⁺CD25⁺ T cells. However, the precise role of these accumulating regulatory T cells was not clarified in arthritis pathology. We generated B47+Foxp3 transduced cells and three groups of controlled gene transfer, Mcok, B47 alone and Foxp3 alone. The reconstituted regulatory T cell group, B47+Foxp3, significantly

suppressed the development of arthritis (FIG. 2B). The Foxp3-alone transduced group suppressed arthritis only marginally. The titers of anti-type II collagen antibodies were not different in these experimental groups. We next evaluated gene expression of inguinal lymph nodes and foot with quantitative PCR. Among cytokines important for arthritis progression, TNF-alpha, IL-17A, and IL-1beta were significantly suppressed. A suppressive cytokine, IL-10, was not upregulated in B47+Foxp3 group. In inguinal lymph nodes, the expression of TNF-alpha, IL-17A, and IL-1beta were not suppressed in B47+Foxp3 group. On histologic examination, although control groups showed severe inflammation, B47+Foxp3 group showed only marginal inflammation. We graded mononuclear cell infiltration and cartilage/bone destruction by the pannus invasion with histopathological examination. Pannus formation was clearly suppressed in the B47+Foxp3 group. These results suggest that regulatory T cells in the arthritis site suppress bone destruction as well as inflammation. In contrast, Foxp3-transduced T cells without antigen specificity were not sufficient for arthritis suppression. Reconstituted regulatory cells also showed effective suppression when transferred after the onset of arthritis when the average arthritic score reached around 2 point. Foxp3-expressing T cells with arthritis-associated TCRs were evidently effective in arthritis suppression. Once activated, regulatory T cells exhibit suppression in an antigen-nonspecific manner.²⁷ However, antigen specificity is important in migration and expansion of regulatory T cells.^{28,29} Indeed, antigen-specific regulatory T cells are efficient in suppression of various autoimmune diseases. The problem is how to obtain enough organ-antigen-specific regulatory T cells for therapeutic transfer. TCR and Foxp3 gene transfer is one possible approach to overcome this problem. In the CIA treatment of polyclonal regulatory T cells, 20 mouse spleens were required to treat 1 mouse.³⁰ In contrast, about a quarter of splenocytes were used to treat one mouse in our experiment.

CONCLUSION

Taking these results together, the system illustrated in the FIGURE 2 was shown to be feasible for use in experimental animals. Recently, the clinical appreciation of retroviral TCR gene transfer was reported in the treatment of melanoma patients. T cells transduced with melanoma antigen-specific TCRs suppressed disease progression in patients with advanced melanoma.³¹ This result showed the essential efficacy and safety of TCR gene transfer in the human. Therefore, autoimmune disease can be a suitable target for TCR gene transfer.

We propose that TCR gene cloning, using the information of TCR clonal analysis and reconstitution of the TCR function by gene transfer, would be a promising strategy for antigen-specific immunotherapy in autoimmune disorders.

ACKNOWLEDGMENTS

This work was supported by grants from the Japan Society for the Promotion of Science, Ministry of Health, Labor and Welfare and the Ministry of Education, Culture, Sports, Science and Technology of Japan.

REFERENCES

1. JACOBSON, D.L., S.J. GANGE, N.R. ROSE & N.M. GRAHAM. 1997. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. *Clin. Immunol. Immunopathol.* **84**: 223–243.
2. LEACH, M.W., E.A. SNYDER, D.P. SINHA & I.Y. ROSENBLUM. 1997. Safety evaluation of recombinant human interleukine-4. I. Preclinical studies. *Clin. Immunol. Immunopathol.* **83**: 8–11.
3. OLSEN, N.J. & C.M. STEIN. 2004. New drugs for rheumatoid arthritis. *N. Engl. J. Med.* **350**: 2167–2179.
4. VANDERLUGT, C.L. & S.D. MILLER. 2002. Epitope spreading in immune-mediated diseases: implications for immunotherapy. *Nat. Rev. Immunol.* **2**: 85–95.
5. YAMAMOTO, K., K. MASUKO-HONGO, A. TANAKA, *et al.* 1996. Establishment and application of a novel T cell clonality analysis using single-strand conformation polymorphism of T cell receptor messenger signals. *Human Immunol.* **48**: 23–31.
6. YAMAMOTO, K., H. SAKODA, T. NAKAJIMA, *et al.* 1992. Accumulation of multiple T cell clonotypes in the synovial lesions of patients with rheumatoid arthritis revealed by a novel clonality analysis. *Int. Immunol.* **4**: 1219–1223.
7. IWAKURA, Y., M. TOSU, E. YOSHIDA, *et al.* 1991. Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-1. *Science* **253**: 1026–1028.
8. KOBARI, Y., Y. MISAKI, K. SETOGUCHI, *et al.* 2004. T cell accumulating in the inflamed joints of spontaneous murine model of rheumatoid arthritis become restricted to common clonotypes during disease progression. *Int. Immunol.* **16**: 131–138.
9. KOMAGATA, Y., K. MASUKO, F. TASHIRO, *et al.* 1996. Clonal prevalence of T cells infiltrating into the pancreas of prediabetic non-obese diabetic mice. *Int. Immunol.* **8**: 807–814.
10. ZHOU, G., K. FUJIO, A. SADAKATA, *et al.* 2004. Identification of systemically expanded activated T cell clones in MRL/lpr and NZB/W F1 lupus model mice. *Clin. Exp. Immunol.* **136**: 448–455.
11. KENT, S.C., Y. CHEN, L. BREGOLI, *et al.* 2005. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. *Nature* **435**: 224–228.
12. VAN DEN ELZEN, P., J.S. MENEZES, A. AMETANI, *et al.* 2004. Limited clonality in autoimmunity: drivers and regulators. *Autoimmunity Review* **3**: 524–529.
13. HUANG, J.C., R.J. OBER & E.S. WARD. 2005. The central residues of a T cell receptor sequence motif are key determinants of autoantigen recognition in murine experimental autoimmune encephalomyelitis. *Eur. J. Immunol.* **35**: 299–304.

14. HOFBAUER, M., S. WIESENER, H. BABBE, *et al.* 2003. Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. *Proc. Natl. Acad. Sci. USA.* **100**: 4090–4095.
15. AMRANI, A., J. VERDGUIER, S. SERRA, *et al.* 2000. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. *Nature* **406**: 739–742.
16. KEDZIERSKA, K., S.J. TURNER & P. DOHERTY. 2004. Conserved T cell receptor usage in primary and recall responses to an immunodominant influenza virus nucleoprotein epitope. *Proc. Natl. Acad. Sci. USA* **101**: 4942–4947.
17. MALHERBE, L., C. HAUSL, L. TEYTON & M.G. MCHEYZER-WILLIAMS. 2004. Clonal selection of helper T cells is determined by an affinity threshold with no further skewing of TCR binding properties. *Immunity* **21**: 669–679.
18. FACCHINETTI, A., S.D. SANTA, S. MEZZALIRA, *et al.* 2005. A large number of T lymphocytes recognize Moloney-murine leukemia virus-induced antigens, but a few mediate long-lasting tumor immunosurveillance. *J. Immunol.* **174**: 5398–5406.
19. FUJIO, K., Y. MISAKI, K. SETOGUCHI, *et al.* 2000. Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. *J. Immunol.* **165**: 528–532.
20. MOHAN, C., S. ADEM, V. STANIK & S.K. DATTA. 1993. Nucleosome: a major immunogen for pathogenic autoantigen-inducing T cells of lupus. *J. Exp. Med.* **177**: 1367–1381.
21. KALIYAPERULAL, A., C. MOHAN, W. WU & S.K. DATTA. 1996. Nucleosomal peptide epitope for nephritis-inducing T helper cells of murine lupus. *J. Exp. Med.* **183**: 2459–2469.
22. FUJIO, K., A. OKAMOTO, H. TAHARA, *et al.* 2004. Nucleosome-specific regulatory T cells engineered by triple gene transfer suppress a systemic autoimmune disease. *J. Immunol.* **173**: 2118–2125.
23. FUJIO, K., A. OKAMOTO, Y. ARAKI, *et al.* 2006. Gene therapy of arthritis with TCR isolated from the inflamed paw. *J. Immunol.* **177**: 8140–8147.
24. TAHARA, H., K. FUJIO, Y. ARAKI, *et al.* 2003. Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte. *J. Immunol.* **171**: 2154–2160.
25. VAN AMELSFORT, J. M., K.M. JACOBS, J.W. BIJLSMA, *et al.* 2004. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. *Arthritis Rheum.* **50**: 2775–2785.
26. DE KLEER, I.M., L.R. WEDDERBURN, L.S. TAAMS, *et al.* 2004. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. *J. Immunol.* **172**: 6435–6443.
27. YU, P., R.K. GREGG, J.J. BELL, *et al.* 2005. Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen. *J. Immunol.* **174**: 6772–6780.
28. TANG, Q., K.J. HENRIKSEN, M. BI, *et al.* 2004. *In vitro*-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. *J. Exp. Med.* **199**: 1455–1465.
29. TARBELL, K.V., S. YAMAZAKI, K. OLSON, *et al.* 2004. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. *J. Exp. Med.* **199**: 1467–1477.

30. MORGAN, M.E., R. FLIERMAN, L.M. VAN DUIVE NVOORDE, *et al.* 2005. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. *Arthritis Rheum.* **52**: 2212–2221.
31. MORGAN, R.A., M.E. DUDLEY, J.R. WUNDERLICH, *et al.* 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science* **314**: 126–129.

The NEW ENGLAND JOURNAL of MEDICINE

VOL. 357 NO. 12

ESTABLISHED IN 1812

SEPTEMBER 20, 2007

WWW.NEJM.ORG



1178 THIS WEEK IN THE JOURNAL

PERSPECTIVE

- 1173 Health Care for All? M.G. Bloche
1175 Eulogy for a Quality Measure T.H. Lee

ORIGINAL ARTICLES

- 1179 Outcomes at 2 Years of Age after Repeat Doses
of Antenatal Corticosteroids
C.A. Crowther and Others
1190 Long-Term Outcomes after Repeat Doses
of Antenatal Corticosteroids
R.J. Wapner and Others
1199 TRAF1-C5 as a Risk Locus for Rheumatoid Arthritis
— A Genomewide Study
R.M. Plenge and Others
1210 A Polymorphism in the CTGF Promoter Region
Associated with Systemic Sclerosis
C. Fonseca and Others

SPECIAL ARTICLE

- 1221 Shattuck Lecture: We Can Do Better — Improving
the Health of the American People
S.A. Schroeder

CLINICAL PRACTICE

- 1229 Gynecomastia
G.D. Braunstein

IMAGES IN CLINICAL MEDICINE

- 1238 Emphysematous Cholecystitis
Y. Shrestha and S. Trottier
e13 Herpetic Glossitis
C.-C. Chan and H.-C. Chiu

**CASE RECORDS OF THE MASSACHUSETTS
GENERAL HOSPITAL**

- 1239 A Man with Gastric Cancer and Lung Nodules
E.T. Ryan, S.L. Aquino, and R.L. Kradin

EDITORIALS

- 1248 Prenatal Corticosteroids — Early Gain,
Long-Term Questions
A.D. Stiles
1250 Lessons from a Genomewide Association Study
of Rheumatoid Arthritis
K. Yamamoto and R. Yamada

1252 **CORRESPONDENCE**

- Estrogen Therapy and Coronary-Artery Calcification
Surgical versus Nonsurgical Treatment for Back Pain
Adjuvant Mitotane in Adrenocortical Carcinoma
Prevention and Treatment of Major Blood Loss
Erythropoietins in Oncology
Recognizing Iodine Deficiency in Iodine-Replete
Environments
Visual Loss after Povidone-Iodine Pleurodesis

1266 **BOOK REVIEWS**

1269 **CONTINUING MEDICAL EDUCATION**

Lessons from a Genomewide Association Study of Rheumatoid Arthritis

Kazuhiko Yamamoto, M.D., Ph.D., and Ryo Yamada, M.D., Ph.D.

Rheumatoid arthritis is a chronic inflammatory disorder in which the articular joints are gradually destroyed. Occasionally there is systemic involvement, which can include vasculitis in various organs and pulmonary fibrosis. The disease has multifactorial causes to which genetic and environmental factors are thought to contribute. The presence of autoantibodies to cyclic citrullinated peptide (CCP) is specific to rheumatoid arthritis; although the mechanistic significance of these autoantibodies is obscure, their detection contributes both to the differential diagnosis and to a prediction of the severity of joint destruction. Rheumatoid arthritis causes substantial morbidity and mortality and is sometimes accompanied by severe infection or accelerated atherosclerosis.

During the past couple of decades, therapy for rheumatoid arthritis has been improved through the introduction of new antirheumatic drugs, such as the antimetabolite and antifolate drug methotrexate, and biologic therapeutics, such as antagonists to tumor necrosis factor (TNF). However, these treatments can have adverse effects,¹ and responsiveness to these treatments varies considerably. Perhaps “personalized medicine” may one day address such variation. An improved understanding of the genetic causes of the disease represents a step toward this goal and the development of other therapeutic approaches.

The article by Plenge et al.² in this issue of the *Journal* is therefore welcome. The authors report the results of a genomewide association study of an anti-CCP-positive subclass of rheumatoid arthritis. It is reassuring that the authors observed associations between rheumatoid arthritis and loci in and around *HLA-DRB1* and *PTPN22*; these loci have been repeatedly implicated as genetic risk factors in persons of European descent. The authors also identified a new locus, containing *TRAF1* and *C5*, through the use of a multistage study design with multiple samples. An earlier large-scale linkage-disequilibrium study and subsequent replication studies implicated a variant of *PADI4* as a risk factor for rheumatoid arthritis.³ This variant would seem to have a more potent effect in Asian populations than in those of

European descent. Variants of these genes are believed to confer a risk for the development of rheumatoid arthritis by affecting the presentation of autoantigens (in the case of *HLA-DRB1*), T-cell-receptor signal transduction (in the case of *PTPN22*), and the citrullination of proteins, targets of anti-CCP antibodies (in the case of *PADI4*). Variant *TRAF1* may modify signal transduction through TNF receptors 1 and 2; variant *C5* may amplify complement activation in the joints of patients with rheumatoid arthritis.

The genomewide association approach has yielded a wealth of new genetic susceptibility loci in other common and complex genetic disorders.⁴ The completion of the Human Genome Project and the development of large-scale public databases of human genetic heterogeneity and high-throughput genotyping technology have enabled researchers to carry out case-control association studies on thousands of samples with several hundreds of thousands of markers throughout the human genome. The scale of genomewide association studies continues to grow, and the number of markers used in such studies will soon approximate or exceed a million. It is not unrealistic to expect that the entire genome of all samples will be sequenced in the not-too-distant future.

An advantage of genomewide association studies, as compared with more typical association studies that test for a connection between disease and candidate-gene markers, is that they screen most of the genes in the human genome — thus allowing the investigator to identify new mechanisms of disease susceptibility. Because genomewide association mapping is achieving ever higher resolution and studies are realizing stronger statistical power with every increase in sample size, it is likely that we will have a catalogue of genes with variants for susceptibility to rheumatoid arthritis with various degrees of risk within several years.

What is the principal challenge to the application of findings from genetic mapping studies to clinical medicine? The variant-specific functional differences responsible for common diseases are smaller than those of mutations responsible

for monogenic disorders, so showing that such variants have a relevant biologic effect (in the form of functional data) is often difficult. Most reports of genomewide association studies, including the one by Plenge et al., do not include tests of function of the identified polymorphisms. In seeking to understand the mechanisms of disease and apply this knowledge to improve diagnosis and treatment in the clinical setting, it is necessary to identify the true causal variants and fathom their effect on gene function. More sensitive and sophisticated methods in molecular biology and immunology are required for the investigation of potentially functional variants — the fruits of current and forthcoming genomewide association studies.

Also critical to reaping the full harvest of clinically relevant information from such an approach is the study of populations of various ancestries. Plenge et al. observed that the odds ratios and P values for the identified polymorphisms were weak in the Swedish population. Moreover, the *TRAF1-C5* locus did not surface in the Wellcome Trust Case Control Consortium study, which included genomewide association of British persons with rheumatoid arthritis.⁴ Although the association of *PADI4* and rheumatoid arthritis has been replicated by several large-scale studies in Japanese populations and a Korean population, it has not been observed in the majority of studies of populations of European descent.

One explanation for the differential detection of specific loci is that genetic variants that are

associated with rheumatoid arthritis may be enriched in one population and not another or may interact with regional environments and thereby assume influence on disease susceptibility. This hypothesis underscores the need for global collaboration and comparisons of multiple ethnic populations. Personalized medicine in the era of genomewide association studies will make few advances unless the scope of clinical research is broadened to include data from many ethnic groups; non-European populations are currently underrepresented.

Dr. Yamamoto reports having equity interest in ImmunoFuture. No other potential conflict of interest relevant to this article was reported.

This article (10.1056/NEJMe078174) was published at www.nejm.org on September 5, 2007.

From the Department of Allergy and Rheumatology, Graduate School of Medicine (K.Y.), and the Laboratory for Functional Genomics, Institute of Medical Sciences (R.Y.), University of Tokyo, Tokyo; the Laboratory for Rheumatic Diseases, Institute of Physical and Chemical Research, Yokohama City (K.Y.); and the Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto (R.Y.) — all in Japan.

1. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. *N Engl J Med* 2004;350:2591-602.
2. Plenge RM, Seielstad M, Padyukov L, et al. *TRAF1-C5* as a risk locus for rheumatoid arthritis — a genomewide study. *N Engl J Med* 2007;357:1199-209.
3. Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of *PADI4*, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. *Nat Genet* 2003;34:395-402.
4. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007;447:661-78.

Copyright © 2007 Massachusetts Medical Society.

IL-17B and IL-17C Are Associated with TNF- α Production and Contribute to the Exacerbation of Inflammatory Arthritis¹

Yumi Yamaguchi,* Keishi Fujio,^{2*} Hirofumi Shoda,* Akiko Okamoto,* Nelson H. Tsuno,[†] Koki Takahashi,[†] and Kazuhiko Yamamoto*

IL-17A is a T cell-derived proinflammatory cytokine that contributes to the pathogenesis of rheumatoid arthritis. Recently, six related molecules have been identified to form the IL-17 family, as follows: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Whereas IL-17A and IL-17F up-regulate IL-6 in synovial fibroblasts, IL-17B and IL-17C are reported to stimulate the release of TNF- α and IL-1 β from the monocytic cell line, THP-1 cell. However, their detailed function remains to be elucidated. We report in this study the effects of IL-17 family on the collagen-induced arthritis (CIA) progression by T cell gene transfer and bone marrow chimeric mice. The mRNA expressions of IL-17 family (IL-17A, IL-17B, IL-17C, and IL-17F) and their receptor (IL-17R and IL-17Rb1) genes in the arthritic paws of CIA mice were elevated compared with controls. Although IL-17A and IL-17F were expressed in CD4⁺ T cells, IL-17B and IL-17C were expressed in the cartilage and in various cell populations in the CIA arthritic paws, respectively. In vitro, IL-17A, IL-17B, IL-17C, and IL-17F induced TNF- α production in mouse peritoneal exudate cells. In vivo, adoptive transfer of IL-17B- and IL-17C-transduced CD4⁺ T cells evidently exacerbated arthritis. Bone marrow chimeric mice of IL-17B and IL-17C exhibited elevated serum TNF- α concentration and the high arthritis score upon CIA induction. Moreover, neutralization of IL-17B significantly suppressed the progression of arthritis and bone destruction in CIA mice. Therefore, not only IL-17A, but also IL-17B and IL-17C play an important role in the pathogenesis of inflammatory arthritis. *The Journal of Immunology*, 2007, 179: 7128–7136.

Interleukin-17A is a T cell-derived proinflammatory cytokine that is involved in the development of rheumatoid arthritis (RA).³ IL-17A was originally named CTLA-8 after being cloned from activated T cells, and shares 57% homology to the protein encoded by the open reading frame 13 gene of the T lymphotropic herpesvirus saimiri (1). IL-17A is present at significant levels in the synovium and synovial fluid of patients with RA (2, 3). IL-17A is a potent inducer of various cytokines such as IL-1, TNF- α , and IL-6. T cell IL-17A stimulates the production of IL-1 and TNF- α from human PBMC-derived macrophages in vitro (4). IL-17A also enhances IL-1-mediated IL-6 production by RA synoviocytes in vitro as well as TNF- α -induced synthesis of IL-1, IL-6, and IL-8 (5, 6). These results indicate that IL-17A synergizes with IL-1 and TNF- α and contributes to inflammation of RA.

In vivo studies, systemic as well as local overexpression of IL-17A in collagen-induced arthritis (CIA) has been shown to accelerate the onset of CIA and to aggravate the joint pathology (7). Moreover, treatment with anti-IL-17A Abs after the onset of CIA reduces the joint inflammation and histologic destruction of cartilage (8). IL-17A deficiency protects IL-1R antagonist-deficient mice from spontaneous development of destructive arthritis (9). Therefore, IL-17A plays a crucial role in the pathogenesis of arthritis through synergistic effects with IL-1 and TNF- α . However, IL-17A can directly induce joint destruction in an IL-1-independent manner and can bypass TNF-dependent arthritis (7, 10). This suggests that there is an IL-17A-dependent pathway to the destructive arthritis and anti-IL-17A cytokine therapy is an additional new antirheumatic strategy for RA besides anti-TNF/anti-IL-1 therapy.

Recently, the IL-17 family was determined to consist of six related molecules, as follows: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. These molecules have a molecular mass of 20–30 kDa and consist of 163–202 aa that bear 20–50% homology to IL-17A, especially within the C-terminal region. They share four conserved cysteine residues that may participate in the formation of intermolecular disulfide linkages (11, 12). The different IL-17 family members seem to have very distinct expression patterns, suggesting distinct biological roles.

Interestingly, IL-17F has the highest homology with IL-17A and is also expressed by activated T cells in response to IL-23 stimulation (13–15). However, the precise effect of IL-17F on arthritis has not been clarified. In contrast to the restricted expression of IL-17A and IL-17F, IL-17B mRNA can be detected in a wide range of tissues, including the spinal cord, testis, stomach, small intestine, pancreas, prostate, and ovary (16, 17). It has been recently reported that IL-17B is highly expressed in chondrocytes

*Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; and [†]Department of Transfusion Medicine and Immunohematology, University of Tokyo, Tokyo, Japan

Received for publication April 12, 2007. Accepted for publication September 5, 2007.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This study was supported by Program and Project Grant funding from Japan Society for the Promotion of Science; Ministry of Health, Labour and Welfare; and Ministry of Education, Culture, Sports, Science and Technology.

² Address correspondence and reprint requests to Dr. Keishi Fujio, Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. E-mail address: kfujio-ky@umin.ac.jp

³ Abbreviations used in this paper: RA, rheumatoid arthritis; BCII, bovine type II collagen; BM, bone marrow; CIA, collagen-induced arthritis; mIL, murine IL; MMP, matrix metalloproteinase; PEC, peritoneal exudate cell; pMIG, murine stem cell virus/internal ribosome entry site/GFP.

Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/\$2.00

that are located at the mid and deep zones of normal bovine articular cartilage (11). In contrast, IL-17C expression has been confined only to rare expression sequence tags in adult prostate and fetal kidney libraries (17). However, the cell sources of IL-17B and IL-17C have not been identified in the development of inflammatory arthritis.

A common feature of IL-17 family members is the induction of neutrophil migration. IL-17A and IL-17F both mobilize neutrophils partly through granulopoiesis and CXC chemokine induction (12). Intranasal administration of adenovirus expressing IL-17A, IL-17C, or IL-17F resulted in neutrophilia in the bronchoalveolar lavage (18). Moreover, i.p. injection of human rIL-17B caused marked neutrophil migration in normal mice (17). In contrast, the members can be divided into two groups according to the induction of cytokine production. Although IL-17A and IL-17F up-regulate IL-6 and IL-8 in human fibroblasts (19, 20), IL-17B and IL-17C are reported to stimulate the release of TNF- α and IL-1 β from the monocytic cell line THP-1 (17). Taken together, these results indicate that IL-17 family members induce inflammatory cytokines not only through activated T cells, but also through activated monocytes/macrophages.

Based on the structural and functional similarities among IL-17 family members, we speculated that not only IL-17A, but also other IL-17 family members are involved in the pathogenesis of many inflammatory and autoimmune disorders, especially in the development of RA. We focused on IL-17A, IL-17B, IL-17C, and IL-17F, which can affect inflammatory cytokine production of fibroblasts and macrophages. Recently, IL-17C expression in synovial fluid mononuclear cells and PBMCs of RA patients was reported (21). However, the biological effect of IL-17 family members in arthritis has not been analyzed.

In the present study, we investigated the expression and effect of IL-17 family members in arthritis. In vitro, not only IL-17A, but also IL-17B and IL-17C induced the mRNA expression of inflammatory cytokines such as IL-1 β , IL-6, and IL-23 in the 3T3 cell line and peritoneal exudate cells (PECs). The supernatant of the PECs stimulated with each IL-17 family member all increased TNF- α production significantly compared with controls. In vivo, CD4⁺ T cells transduced with each of IL-17B, IL-17C, or IL-17F exacerbated CIA in mice to the same degree as CD4⁺ T cells transduced with IL-17A. Mice reconstituted with bone marrow (BM) cells transduced with each of IL-17B, IL-17C, or IL-17F suffered from severe CIA. Moreover, neutralization of IL-17B significantly suppressed the progression of arthritis and bone destruction in CIA mice. Our results suggest that not only IL-17A, but also the other IL-17 family members (IL-17B, IL-17C, and IL-17F) are associated with inflammatory cytokines such as IL-1 and TNF- α and contribute to the exacerbation of autoimmune arthritis.

Materials and Methods

Animals

DBA/1J mice were purchased from Japan SLC. All mice were used at 6–8 wk of age. All animal experiments were conducted in accordance with the institutional and national guidelines.

Collagen-induced arthritis

CIA was induced, as described previously (22–24). In brief, bovine type II collagen (BCII) (Chondrex) was emulsified with an equal volume of CFA (Chondrex). DBA/1J mice were immunized intradermally at the base of the tail with 100 μ g of BCII emulsified with CFA. On day 21, the mice were boosted by intradermal injection with 100 μ g of BCII emulsified with IFA (Difco). The arthritis score was determined by erythema, swelling, or ankylosis per paw, as described previously (25, 26). The clinical arthritis score was defined as the sum of the scores of all four paws of each mouse.

Cytokines and cell lines

Recombinant murine IL (mIL)-17A, mIL-17B, mIL-17C, and mIL-17F were obtained from R&D Systems. The mouse fibroblast cell line 3T3 was obtained from American Type Culture Collection. This cell line was cultured with RPMI 1640 (Invitrogen Life Technologies) medium supplemented with 10% FCS, 2 mM γ -glutamine, 100 U/ml penicillin, 100 μ g/ml streptomycin, and 5×10^{-5} M 2-ME. Ba/F3 cells were maintained in RPMI 1640 medium supplemented with 10% FCS, 2 mM γ -glutamine, 100 U/ml penicillin, 100 μ g/ml streptomycin, and 1 ng/ml rIL-3 (R&D Systems).

Murine PECs

Murine PECs were isolated after i.p. injection of 3 ml of 5% sterile fluid Brewer's thioglycolate broth (Sigma-Aldrich) into 8-wk-old DBA/1J mice (27). After culture of the PECs in a 6-well plate for 2 h, floating cells were removed by extensive washing, and attached cells were maintained in the medium described above for 3 days. More than 80% of the cultured cells were macrophages as determined by flow cytometric analysis of CD11b-positive cells. The following recombinant murine cytokines were added to the culture medium and incubated for 24 h: 50 ng/ml mIL-17A, mIL-17B, mIL-17C, or mIL-17F.

Preparation of retroviral constructs of mIL-17 family cDNAs

mIL-17A, mIL-17B, mIL-17C, and mIL-17F were isolated from the murine T lymphocyte cDNA library according to the reported nucleotide sequence from National Center for Biotechnology Information (mIL-17A NM_010552; mIL-17B NM_019508; mIL-17C NM_145834; mIL-17F NM_145856). The full-length fragments were subcloned into retrovirus vector murine stem cell virus/internal ribosome entry site/GFP (pMIG), as described previously (28).

Production of retroviral supernatants and retroviral transduction

Retroviral supernatants were obtained by transfection of pMIG carrying each of the IL-17 family genes into PLAT-E packaging cell lines using FuGENE 6 transfection reagent (Roche Diagnostic System), as described previously (29). For the detection of GFP-positive cells, we used an EPICS XL flow cytometer (Beckman Coulter).

Gene transduction to mouse splenocytes and adoptive transfer

Total splenocytes were cultured for 48 h in the presence of Con A (10 μ g/ml) (Sigma-Aldrich) and mIL-2 (50 ng/ml) (R&D Systems). Retroviral gene transduction was performed, as described previously (30, 31). A CD4⁺ T cell population was prepared by negative selection by MACS with anti-CD19 mAb, anti-CD11c mAb, and anti-CD8a mAb (BD Pharmingen). The gene-transduced CD4⁺ T cells were suspended in PBS and injected i.v. (1×10^7) at 23 days after the first immunization of BCII.

BM precursor cell isolation, infection, and transfer

BM precursor cell isolation, retrovirus infection, and transfer were performed, as described previously (32). In brief, DBA/1J mice were treated with 5 mg/body 5-fluorouracil (Sigma-Aldrich) dissolved in PBS. After 5 days, BM cells were harvested and cultured with 50 ng/ml mIL-3, mIL-6, and murine stem cell factor (R&D Systems) for 48 h. Then the BM cells were spin infected with the retrovirus supernatants with 16 μ g/ml polybrene (Sigma-Aldrich) for 90 min at 2400 rpm and 25°C. Recipient mice were treated by 700 rad of whole-body radiation and were injected with 1×10^6 of the BM cells i.v. Recipient mice were maintained for 6 wk until analysis or immunization.

RNA isolation, cDNA synthesis, and quantitative real-time PCR

RNA of the cells was extracted using an RNeasy Micro Kit and RNeasy Mini Kit (Qiagen). RNA from the tissues was isolated by the acid guanidinium thiocyanate-phenol-chloroform extraction method using ISOGEN (Nippon Gene). RNA was reverse transcribed to cDNA with random primers (Invitrogen Life Technologies) and Superscript III, according to the manufacturer's protocol (Invitrogen Life Technologies). To determine the cellular expression of each protein, quantitative real-time PCR analysis was performed using an iCycler (Bio-Rad). The PCR mixture consisted of 25 μ l of SYBR Green Master Mix (Qiagen), 15 pmol of forward and reverse primers, and the cDNA samples, in a total volume of 50 μ l. We calculated the quantitative PCR data with δ cycle threshold method, and relative RNA abundance was determined based on control β -actin abundance. To measure the relative efficiency,

amplifications were performed on the serial diluted cDNA samples using primers for the target and the reference (β -actin) genes. We made plots of the log cDNA dilution vs δ cycle threshold, and confirmed that the efficiencies of the target and the reference genes were similar because the absolute value of the slope was close to zero (data not shown) (33, 34). The primer pairs used in the quantitative real-time PCR were as follows: mouse IL-17A, sense 5'-GCTCCAGAAGGCCCTCAGA-3', antisense 5'-AGCTTTCCTCCGCATTGA-3'; mouse IL-17B, sense 5'-CGGTGCCTATGTTTGGGTTGC-3', antisense 5'-GGGTTG GTGGTTGGCTCAGAA-3'; mouse IL-17C, sense 5'-CACAGATGAG AACCGCTACCC-3', antisense 5'-GCGGATGAACCTCGGTGTGGA A-3'; mouse IL-17F, sense 5'-CAACGCTGCATACAAAAATCA-3', antisense 5'-TTAAGTGAGGCATTGGGAACA-3'; mouse IL-17R, sense 5'-CCACTCTGTAGCACCCCAATG-3', antisense 5'-CCTGGA GATGTAGCCCTGGTC-3'; mouse IL-17R_{h1}, sense 5'-GCAAGGAA GGAGCACGAAGAC-3', antisense 5'-CTCGGCGATTTTCTTTTCT G-3'; mouse TNF- α , sense 5'-CATCTTCTCAAAATTCGAGTGACA A-3', antisense 5'-TGGGAGTAGACAAGGTACAACCC-3'; mouse IL-1 β , sense 5'-CAACCAACAAGTGATATTCTCCATG-3', antisense 5'-GATCCACACTCTCCAGCTGCA-3'; mouse IL-6, sense 5'-CACT TCACAAGTCGGAGGCTTA-3', antisense 5'-GCAAGTGCATCATC GTTGTTC-3'; mouse IL-23, sense 5'-TGGCATCGAGAAACTGTGAG A-3', antisense 5'-TCAGTTCGATTTGGTAGTCTCTGTTA-3'; and mouse β -actin, sense AGAGGGAAATCGTGCGTGAC-3', antisense 5'-CAATAGTGATGACCTGGCCGT-3'.

Immunoassays of cytokines and anti-type II collagen Ab

The concentrations of mIL-6, mTNF- α , and mIL-17A in mouse sera and culture supernatants were measured by sandwich ELISA, according to the manufacturer's protocol (BD Pharmingen). An automatic microplate reader (Bio-Rad 550) was used to measure the OD. Mouse serum IgG anti-type II collagen Ab titer was measured, as previously described (35).

Isolation of cartilage

Murine articular cartilage was isolated from patellae, as described previously (36). In brief, patellae were decalcified in 3.5% EDTA for 4 h at 4°C, when the whole cartilage layer was stripped off. Because old cartilage is more calcified, decalcification of the patellae of old mice (>3 mo) was performed overnight at 4°C.

Cell purification

Briefly, the arthritic paws of the CIA mice were cut into pieces, digested with collagenase type IV (Sigma-Aldrich), and stained with mAbs (Fc blocking with anti-mouse CD16/CD32 mAb, and staining with anti-mouse CD3-PE mAb, anti-mouse CD4-allophycocyanin mAb, anti-mouse CD11b-FITC mAb, anti-mouse CD11c-FITC mAb, anti-mouse CD19-FITC mAb, biotinylated anti-mouse I-A/I-E (MHC class II) mAb, and streptavidin PE Ab that were obtained from BD Pharmingen). Cell sorting of a specific cell population was performed with a FACSVantage flow cytometer (BD Biosciences).

Intracellular cytokine staining and flow cytometry

IL-17 family expressions of Ba/F3 cells transduced with each of IL-17 family members were examined using intracellular cytokine staining. Ba/F3 cells were infected with the retroviral supernatants in the presence of 10 μ g/ml polybrene (Sigma-Aldrich) for 120 min. These cells were stained with anti-mouse IL-17A mAb conjugated to PE (BD Pharmingen), biotinylated anti-mouse IL-17B polyclonal Ab (R&D Systems), anti-mouse IL-17C polyclonal Ab (R&D Systems), and anti-mouse IL-17F mAb (R&D Systems), respectively. Bovine anti-goat IgG-PE (Santa Cruz Biotechnology) and F(ab')₂ goat anti-rat IgG PE (Serotec) were used as secondary reagents for IL-17C and IL-17F staining, respectively. Cell fixation and permeabilization were performed using Cytofix/Cytoperm reagent (BD Pharmingen), according to the manufacturer's protocol (BD Pharmingen), and analyzed by flow cytometry. Splenocytes isolated from BM chimeric mice of IL-17A were also stained with anti-mouse IL-17A mAb in the same way.

Anti-IL-17B Ab treatment in CIA mice

CIA was induced in DBA/1J mice, as described above. Mice exhibited the first clinical signs of arthritis (arthritis score between 1 and 2) and were injected i.p. with 100 μ g of polyclonal anti-mouse IL-17B Abs (R&D Systems). PBS was i.p. injected as a control. Arthritis was assessed using a scoring system, as described above. Mice were sacrificed at 10 days after the onset of arthritis, and the paws were removed. Joint pathology was evaluated on decalcified H&E-stained sections.

Histopathology

The tarsal joints of sacrificed CIA mice were embedded in paraffin wax after 10% formaldehyde fixation and decalcification. The sections were stained with H&E. Synovial tissues were graded by mononuclear cell infiltration and pannus invasion, as described previously (37).

Statistical analysis

Data are expressed as the means \pm SD. All results were obtained by at least three independent experiments. Statistical significance was determined by the Mann-Whitney *U* test and unpaired Student's *t* tests. A value of *p* < 0.05 was considered statistically significant.

Results

IL-17 family genes (IL-17A, IL-17B, IL-17C, and IL-17F) were highly expressed in the arthritic paws of CIA mice

First, we examined the expressions of IL-17 family members and IL-17Rs in the arthritic paws of CIA mice by quantitative PCR. The mRNA expressions of all IL-17 family genes examined (IL-17A, IL-17B, IL-17C, and IL-17F) were highly elevated in the arthritic paws compared with the controls. In accordance with previous report of high *in vivo* expression of IL-17R in RA (38), mRNA expressions of IL-17Rs (IL-17R and IL-17R_{h1}) were also elevated (Fig. 1A). As expected, the mRNA expressions of inflammatory cytokines (TNF- α , IL-1 β , IL-6, and IL-23) were also elevated in the arthritic paws compared with controls (Fig. 1B).

We next examined cell populations in the arthritic paws of CIA mice that express IL-17 family members. Subpopulations of the cells were sorted with various cell surface markers using a flow cytometer. As expected, CD4⁺ T cells expressed IL-17A and IL-17F significantly. IL-17B was expressed exclusively in the inflammatory cartilage of CIA mice. In contrast, IL-17C was expressed in a broad range of cells, i.e., CD4⁺ T cells, CD11b⁺ MHC class II⁺ macrophages, and CD11c⁺ MHC class II⁺ dendritic cells (Fig. 1C). These results suggested that CD4⁺ T cells mainly express IL-17 family members, especially IL-17A, IL-17C, and IL-17F, at the inflammatory site.

IL-17 family induced several proinflammatory cytokines

We next investigated whether IL-17 family members have an influence on mouse fibroblast cell lines and mouse peritoneal macrophages. Cells of the mouse fibroblast line 3T3 were cultured with each of the IL-17 family members (50 ng/ml), and cytokine expression was examined after 24 h of incubation. IL-17A induced IL-1 β and IL-6 expressions, as previously reported (2). Moreover, IL-17B, IL-17C, and IL-17F also induced IL-1 β expression in 3T3 (Fig. 2A).

To examine the effects of IL-17 family members on mouse macrophages, thioglycolate-elicited PECs were isolated and cultured with each of the IL-17 family members (50 ng/ml). IL-17A induced IL-1 β , IL-6, and IL-23 expressions in PECs. Interestingly, IL-17B also induced IL-1 β , IL-6, and IL-23 expressions. Moreover, IL-17C induced IL-1 β and IL-23 expressions in PECs (Fig. 2B). In addition, PECs stimulated with every IL-17 family member produced significantly increased amount of TNF- α protein compared with the control, and PECs stimulated with IL-17A and IL-17B produced significantly increased amount of IL-6 protein (Fig. 2C). These results suggested that IL-17A, IL-17B, IL-17C, and IL-17F stimulate fibroblasts and macrophages to produce inflammatory cytokines.